Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1
Thomas Boyer(University of Arizona), Howard Monsour(Center for Digestive and Liver Diseases), Marco Olivera‐Martinez, Fredric Regenstein, John R. Lake(Gilead Sciences (United States)), Madhavi Rudraraju, Adnan Said, Paul Y. Kwo(Indiana University School of Medicine), Kirti Shetty, Stephen D. Zucker, Hugo E. Vargas(Mayo Clinic in Arizona), K. Rajender Reddy(University of Pennsylvania Health System), Tarek Hassanein, Terry Box, Alex S. Befeler(Saint Louis University Hospital), Yuri Genyk, Khurram Jamil(Mallinckrodt (United States)), Michael P. Curry, Samuel H. Sigal(New York University), Kevin Korenblat(Washington University in St. Louis), Andrea Duchini, Rohit Satoskar, Jacqueline G. O’Leary(Baylor University Medical Center), Michael K. Porayko, Joseph F. Buell, Florence Wong(University of Toronto), K. Gautham Reddy, Jasmohan S. Bajaj(Virginia Commonwealth University), Eyob Feyssa, Arun J. Sanyal(Virginia Commonwealth University), David S. Barnes, R. Todd Frederick(California Pacific Medical Center), S. Chris Pappas, Priya Grewal, Vishal Patel, Lorenzo Rossaro(University of California Davis Medical Center), Kris V. Kowdley(Washington State University Spokane), Daniel Ganger(Northwestern University), Santiago J. Muñoz(Einstein Medical Center Philadelphia), Marie Noëlle Pépin, Nikroo Hashemi, Nathan J. Shores, Paul Angulo(University of Kentucky), Atif Zaman, David Kravetz, Víctor Araya, Ram Subramanian(Emory University), Sukru Emre(Yale University), Maria Hernandez, Marlyn J. Mayo(The University of Texas Southwestern Medical Center)
Cited by 305
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k